Related Experiment Video

Updated: Jun 9, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association

Craig J Beavers, Jo E Rodgers, Aaron J Bagnola

    Circulation
    |March 7, 2022
    PubMed

    Insights

    Drug interactions are critical in cardio-oncology due to complex treatments. Understanding and managing these interactions, whether pharmacokinetic or pharmacodynamic, is key to ensuring patient safety and treatment efficacy.

    Area of Science:

    • Cardio-oncology
    • Clinical Pharmacology
    • Oncology

    Background:

    • Drug interactions pose significant risks in cardio-oncology due to complex patient profiles and therapies.
    • Both cardiovascular and cancer treatments carry inherent risks that can be exacerbated by drug-drug interactions.

    Purpose of the Study:

    • To provide clinicians with an overview of drug-drug interactions in cardio-oncology.
    • To discuss pharmacodynamic and pharmacokinetic interactions relevant to cardiovascular and cancer medications.

    Main Methods:

    • Review of existing literature on drug interactions in cardio-oncology.
    • Analysis of common cardiovascular and cancer medications and their potential interactions.

    Main Results:

    • Drug interactions can be detrimental, reducing the efficacy or safety of cancer or cardiovascular therapies.
    • Understanding interaction mechanisms (pharmacokinetic and pharmacodynamic) is crucial.

    Conclusions:

    • Clinicians must be aware of potential drug-drug interactions in cardio-oncology.
    • Mitigation strategies include recognition, alternative medications, and careful monitoring.
    Keywords:
    AHA Scientific Statementscardiovascular systemdrug interactionsmedical oncologypharmacokineticspharmacology

    More Related Videos

    Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening10:39

    Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening

    Published on: April 15, 2017

    Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes08:47

    Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

    Published on: December 16, 2022

    Related Concept Videos

    Heart Failure Drugs: Inotropic Agents01:26

    Heart Failure Drugs: Inotropic Agents

    Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
    Heart Failure Drugs: Diuretics01:22

    Heart Failure Drugs: Diuretics

    Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
    Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

    Cardiovascular Drugs: Classification based on Therapeutic Indications

    Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
    FDA Approved Drugs: Changes to Approved Drugs01:26

    FDA Approved Drugs: Changes to Approved Drugs

    Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...